EA201690098A1 - Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf - Google Patents

Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf

Info

Publication number
EA201690098A1
EA201690098A1 EA201690098A EA201690098A EA201690098A1 EA 201690098 A1 EA201690098 A1 EA 201690098A1 EA 201690098 A EA201690098 A EA 201690098A EA 201690098 A EA201690098 A EA 201690098A EA 201690098 A1 EA201690098 A1 EA 201690098A1
Authority
EA
Eurasian Patent Office
Prior art keywords
raf
raf kinase
urea
inhibitor
tricyclic compounds
Prior art date
Application number
EA201690098A
Other languages
English (en)
Other versions
EA029412B1 (ru
Inventor
Чаню Чжоу
Голян Чжан
Original Assignee
Бейджин, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейджин, Лтд. filed Critical Бейджин, Лтд.
Publication of EA201690098A1 publication Critical patent/EA201690098A1/ru
Publication of EA029412B1 publication Critical patent/EA029412B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Предложены определенные конденсированные трициклические соединения мочевины и их соли, их композиции и способы их применения.
EA201690098A 2013-06-28 2014-06-27 Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf EA029412B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013078338 2013-06-28
PCT/CN2014/080983 WO2014206343A1 (en) 2013-06-28 2014-06-27 Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors

Publications (2)

Publication Number Publication Date
EA201690098A1 true EA201690098A1 (ru) 2016-06-30
EA029412B1 EA029412B1 (ru) 2018-03-30

Family

ID=52141106

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690098A EA029412B1 (ru) 2013-06-28 2014-06-27 Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf

Country Status (19)

Country Link
US (4) US9670203B2 (ru)
EP (1) EP3013798B1 (ru)
JP (4) JP6380861B2 (ru)
KR (1) KR102272606B1 (ru)
CN (2) CN109369671B (ru)
AU (1) AU2014301816B2 (ru)
BR (1) BR112015032539B1 (ru)
CA (1) CA2916543C (ru)
DK (1) DK3013798T3 (ru)
EA (1) EA029412B1 (ru)
ES (1) ES2686821T3 (ru)
HK (1) HK1217485A1 (ru)
IL (1) IL242973A0 (ru)
MX (1) MX362582B (ru)
NZ (1) NZ716392A (ru)
PT (1) PT3013798T (ru)
SG (1) SG11201600147TA (ru)
WO (1) WO2014206343A1 (ru)
ZA (1) ZA201600513B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
WO2014206344A1 (en) * 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
NZ716392A (en) * 2013-06-28 2017-03-31 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CN116715662A (zh) * 2019-01-25 2023-09-08 百济神州(北京)生物科技有限公司 无定形的b-raf激酶二聚体抑制剂
TW202043225A (zh) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
CN111484490A (zh) * 2019-01-25 2020-08-04 百济神州有限公司 适合大规模生产b-raf激酶二聚体抑制剂的方法
CN111484488A (zh) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20240076272A1 (en) * 2019-10-08 2024-03-07 The Brigham And Women`S Hospital, Inc. Activators of Heme Regulated Inhibitor Kinase (HRI)
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230035031A (ko) 2020-06-05 2023-03-10 킨네이트 바이오파마 인크. 섬유아세포 성장 인자 수용체 키나아제의 억제제
EP4320127A1 (en) 2021-04-05 2024-02-14 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100733D0 (sv) * 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
KR20050033663A (ko) * 2002-09-05 2005-04-12 메디비르 아베 비-뉴클레오시드 역전사효소 억제제
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
BRPI0619514A2 (pt) * 2005-12-08 2011-10-04 Millennium Pharm Inc compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos
PE20080069A1 (es) * 2006-05-15 2008-02-22 Merck & Co Inc Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40)
US8067599B2 (en) 2006-09-06 2011-11-29 Hoffman-La Roche Inc. Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
GB0807609D0 (en) * 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
CN104958294A (zh) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
DK2797888T3 (en) * 2011-12-31 2016-09-19 Beigene Ltd Fused tricyclic compounds as RAF kinase inhibitors
NZ716392A (en) 2013-06-28 2017-03-31 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2014206344A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors

Also Published As

Publication number Publication date
CA2916543C (en) 2023-03-14
CN105452223A (zh) 2016-03-30
US9920055B2 (en) 2018-03-20
BR112015032539B1 (pt) 2022-07-12
CN109369671A (zh) 2019-02-22
AU2014301816B2 (en) 2017-06-01
JP6889311B2 (ja) 2021-06-18
US20190144446A1 (en) 2019-05-16
EP3013798B1 (en) 2018-06-27
US20160368914A1 (en) 2016-12-22
US20180282326A1 (en) 2018-10-04
JP2018184438A (ja) 2018-11-22
JP2016523269A (ja) 2016-08-08
US10208038B2 (en) 2019-02-19
EP3013798A1 (en) 2016-05-04
SG11201600147TA (en) 2016-02-26
KR20160039187A (ko) 2016-04-08
PT3013798T (pt) 2018-11-12
ES2686821T3 (es) 2018-10-22
JP2020143120A (ja) 2020-09-10
EP3013798A4 (en) 2017-02-08
MX362582B (es) 2019-01-24
US20170233391A1 (en) 2017-08-17
EA029412B1 (ru) 2018-03-30
NZ716392A (en) 2017-03-31
ZA201600513B (en) 2018-07-25
JP6380861B2 (ja) 2018-08-29
CN105452223B (zh) 2018-10-02
CN109369671B (zh) 2021-07-27
JP6707584B2 (ja) 2020-06-10
IL242973A0 (en) 2016-02-29
KR102272606B1 (ko) 2021-07-05
JP2021120411A (ja) 2021-08-19
AU2014301816A1 (en) 2016-02-18
JP7207629B2 (ja) 2023-01-18
WO2014206343A1 (en) 2014-12-31
BR112015032539A2 (pt) 2017-07-25
CA2916543A1 (en) 2014-12-31
DK3013798T3 (en) 2018-10-15
US10562899B2 (en) 2020-02-18
MX2016000143A (es) 2016-06-15
US9670203B2 (en) 2017-06-06
HK1217485A1 (zh) 2017-01-13

Similar Documents

Publication Publication Date Title
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
CO2018005368A2 (es) Inhibidores pirazol de acc y usos de los mismos
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692104A1 (ru) Ингибиторы асс и их применения
EA201591962A1 (ru) Ингибиторы акк и их применение
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CR20150524A (es) Compuestos de heteroarilo y sus usos
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201591137A1 (ru) Ингибиторы mk2 и их применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM